+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Months +
All Genders
ID07826767

Study of SGX-001 Gene Therapy Using Patients Own Stem Cells for p47phox Deficiency Chronic Granulomatous Disease in Children and Adults

Led by Somagenetix AG · Updated on 2026-09-17

5

Participants Needed

3

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Chronic granulomatous disease CGD caused by p47phox deficiency p47-CGD is a serious genetic disorder that impairs the function of certain immune cells, leading to severe infections and inflammation that reduce life expectancy. Standard treatments involve daily antimicrobial drugs to prevent infections, but they do not fix the genetic cause. Allogeneic hematopoietic stem cell transplant HSCT is the only cure but carries risks, especially when donors are not ideal matches. This research studies SGX-001, a gene therapy using the patients own stem cells modified to produce the missing protein and restore immune function. Participants receive an infusion of these modified cells. The trial includes patients who need allogeneic HSCT but lack a fully matched sibling donor. The study evaluates the safety and effectiveness of this single treatment. Participants will be followed for safety and treatment response for 12 months after receiving SGX-001. Assessments include measuring immune cell activity and monitoring for safety events. Female participants must avoid pregnancy during treatment and follow-up. Long-term follow-up may continue for up to 15 years to monitor ongoing effects. Overall participation lasts at least one year with additional long-term monitoring possible.

CONDITIONS

Brief Title

Open-label Gene Therapy Study in p47-CGD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here